ArticleFrontiers in oncology2020

Clinical Outcomes for PD-1 Inhibitor Plus Chemotherapy as Second-Line or Later Therapy Compared to PD-1/PD-L1 Inhibitor Alone in Advanced Non-small-cell Lung Cancer.

Xiaoyang Zhai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.